iHeart Japan, a spin-off of Kyoto’s CiRA, will start joint program with Boehringer Ingelheim on cardiac drug safety evaluation

The cooperation is based on the future use of CiRA’s cardiomycetes, derived from personalized human iPS cells, for cardiac drug safety evaluation.

iHeart Japan press release, February 21, 2014